trap staining solution (Beyotime)
Beyotime is a verified supplier 
Beyotime manufactures this product 
99
Structured Review
Beyotime
trap staining solution
Trap Staining Solution, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 2029 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trap+staining+solution/DAPI+Staining+Solution/pmc12272599-57-23-42
Average 99 stars, based on 2029 article reviews
Trap Staining Solution, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 2029 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/trap+staining+solution/DAPI+Staining+Solution/pmc12272599-57-23-42
Average 99 stars, based on 2029 article reviews
trap staining solution - by Bioz Stars,
2026-09
99/100 stars
Images
1) Product Images from "Self-powered intracellular nanogenerator attenuates inflammatory osteolysis through mitochondrial MRS2/Mg 2+ -mediated macrophage repolarization and osteoclastogenesis inhibition"
Article Title: Self-powered intracellular nanogenerator attenuates inflammatory osteolysis through mitochondrial MRS2/Mg 2+ -mediated macrophage repolarization and osteoclastogenesis inhibition
Journal: Materials Today Bio
doi: 10.1016/j.mtbio.2025.102050
Figure Legend Snippet: pBTO inhibited osteoclastogenesis in vitro. (A) TRAP staining in RANKL-treated RAW264.7 cells stimulated with BTO and pBTO. (B) Relative mRNA levels of genes associated with osteoclastogenesis of RAW264.7 cells in the presence of RANKL, BTO or pBTO. (C) JC-1 staining in RANKL-treated RAW264.7 cells stimulated with BTO and pBTO. (D) Schematic diagram of pBTO inhibit osteoclastogenesis of macrophage (∗: p < 0.05, ∗∗: p < 0.01, ∗∗∗∗: p < 0.001).
Techniques Used: In Vitro, Staining
Figure Legend Snippet: pBTO improved inflammatory bone loss by modulating macrophage polarization and osteoclastogenesis in vivo. (A) Designed an mice inflammatory bone loss model. (B) Micro-CT scanning and 3D reconstruction of mice calvarial bone. pBTO inhibited LPS-induced inflammatory bone loss. (C) CD68 + Arg-1 + macrophages (arrow) in calvarial bone matrix under confocal microscope. PBTO increased the number of M2 macrophages. (D) CD68 + iNOS + macrophages (arrow) in calvarial bone matrix under confocal microscope. pBTO decreased the number of LPS-induced M1 macrophages. (E) HE staining of mice calvarial bone showed pBTO decreased LPS-induced inflammatory cell infiltration and bone resorption. (F) TRAP staining of mice calvarial bone showed pBTO decreased the number of osteoclasts.
Techniques Used: In Vivo, Micro-CT, Microscopy, Staining
Related Articles
Incubation:Article Title: Self-powered intracellular nanogenerator attenuates inflammatory osteolysis through mitochondrial MRS2/Mg 2+ -mediated macrophage repolarization and osteoclastogenesis inhibition Article Snippet: Based on our previous research [ ], RAW 264.7 cells were incubated with 100 μg/mL BTO and pBTO, and stimulated with 50 ng/mL RANKL (peprotech, USA) for 3–5 days and then subjected to TRAP staining (Servicebio, China). .. The cells were fixed with 4 % paraformaldehyde for 15 min, permeabilized with 0.1 % Triton X-100 for 20 min, and incubated with Article Title: Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis Article Snippet: Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance.. Eldecalcitol (ED-71), a novel drug for treating osteoporosis, still requires research to overcome high-frequency delivery and low-utilization.. Here, a bone-targeting and multishelled nanoparticles are developed for step-wise release of ED-71. Staining:Article Title: Self-powered intracellular nanogenerator attenuates inflammatory osteolysis through mitochondrial MRS2/Mg 2+ -mediated macrophage repolarization and osteoclastogenesis inhibition Article Snippet: Based on our previous research [ ], RAW 264.7 cells were incubated with 100 μg/mL BTO and pBTO, and stimulated with 50 ng/mL RANKL (peprotech, USA) for 3–5 days and then subjected to TRAP staining (Servicebio, China). .. The cells were fixed with 4 % paraformaldehyde for 15 min, permeabilized with 0.1 % Triton X-100 for 20 min, and incubated with Article Title: Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis Article Snippet: Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance.. Eldecalcitol (ED-71), a novel drug for treating osteoporosis, still requires research to overcome high-frequency delivery and low-utilization.. Here, a bone-targeting and multishelled nanoparticles are developed for step-wise release of ED-71. Quantitative RT-PCR:Article Title: Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis Article Snippet: Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance.. Eldecalcitol (ED-71), a novel drug for treating osteoporosis, still requires research to overcome high-frequency delivery and low-utilization.. Here, a bone-targeting and multishelled nanoparticles are developed for step-wise release of ED-71. Isolation:Article Title: Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis Article Snippet: Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance.. Eldecalcitol (ED-71), a novel drug for treating osteoporosis, still requires research to overcome high-frequency delivery and low-utilization.. Here, a bone-targeting and multishelled nanoparticles are developed for step-wise release of ED-71. cDNA Synthesis:Article Title: Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis Article Snippet: Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance.. Eldecalcitol (ED-71), a novel drug for treating osteoporosis, still requires research to overcome high-frequency delivery and low-utilization.. Here, a bone-targeting and multishelled nanoparticles are developed for step-wise release of ED-71. Reverse Transcription:Article Title: Bone‐Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve Osteoporosis by Reconstruction of Osteogenic‐Osteoclastic Homeostasis Article Snippet: Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance.. Eldecalcitol (ED-71), a novel drug for treating osteoporosis, still requires research to overcome high-frequency delivery and low-utilization.. Here, a bone-targeting and multishelled nanoparticles are developed for step-wise release of ED-71. |
